Adicet Bio:SLEにおけるprula-celのトップラインデータ、2026年9月に予定

Last patient visit completed for the planned Phase 1 analysis of prula-cel in SLE with or without LN. Topline data from 22 patients (13 with ≥12 months follow-up) are now scheduled for release in September 2026. The company also notes FDA alignment on outpatient dosing and ongoing registrational trial design discussions.

主要事実

提出: 2026年9月1日 11:02
イベント: トップライン結果
方向: 中立
企業: ACETAdicet
アセット: prulacabtagene leucel
出典: SEC 8-K
信頼度: 出典あり
12ヶ月患者: 13
解析患者: 22

出典の抜粋

EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1 Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update Prula-cel topline results from planned analysis expected September 2026 FDA clearance of IND for ADI-212 in mCRPC; Phase 1 clinical study expected to initiate in 4Q 2026 Unveiling next-generation in vivo CAR-T platform and pipeline targeting hematological malignancies and solid tumors; first candidate expected to enter clinical development in 2H 2027 REDWOOD CITY, Calif. – September 1, 2026 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell an

SEC 8-K